Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.

Hepato-gastroenterology Pub Date : 2015-03-01

Zheng Zhou, Cong Dai, Wei-Xin Liu

{"title":"Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.","authors":"Zheng Zhou, Cong Dai, Wei-Xin Liu","doi":"","DOIUrl":null,"url":null,"abstract":"Background/aims: TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with conventional therapy.Methodology: The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.Results: Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR = 1.82; 95% CI 1.24 to 2.67) and clinical response (RR = 1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.Conclusion: Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"309-18"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aims: TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with conventional therapy.

Methodology: The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.

Results: Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR = 1.82; 95% CI 1.24 to 2.67) and clinical response (RR = 1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.

Conclusion: Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.

本刊更多论文

英夫利昔单抗和阿达马单抗抗tnf -a治疗对溃疡性结肠炎的疗效与常规治疗的比较:一项荟萃分析。

背景/目的:TNF-α在溃疡性结肠炎(UC)的发病机制中起重要作用。抗肿瘤坏死因子α治疗在UC的治疗中似乎是有益的。目的是评估英夫利昔单抗和阿达木单抗与常规治疗相比治疗UC的有效性。方法:检索Pubmed和Embase数据库，研究英夫利昔单抗和阿达木单抗对UC的疗效。结果:英夫利昔单抗诱导临床反应的效果有统计学意义(RR = 1.67;95% CI 1.12 ~ 2.50)，但在临床缓解方面无统计学意义的影响(RR = 1.63;95% CI 0.84 ~ 3.18)和结肠切除术率降低(RR = 0.54;95% CI 0.26 ~ 1.12)。阿达木单抗在诱导临床缓解方面具有统计学意义(RR = 1.82;95% CI 1.24 ~ 2.67)和临床反应(RR = 1.36;与常规治疗相比，UC的95% CI为1.13至1.64。结论:我们的荟萃分析表明，与常规治疗相比，英夫利昔单抗在诱导UC临床反应方面具有统计学意义，阿达木单抗在诱导UC临床缓解和临床反应方面具有统计学意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepato-gastroenterology 医学-外科

自引率

0.00%

发文量

审稿时长

1.9 months

期刊介绍： Hepato-Gastroenterology has been discontinued as of 2015. Extremely limited quantities of back issues in print available for sale.